Ranger Investment Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Ranger Investment Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-156,717	Closed	-$12.4M	–	146
2017 Q2	$12.4M	Sell	156,717 -127,237	-45%	-$10.4M	0.88%	48
2017 Q1	$23.6M	Sell	283,954 -20,351	-7%	-$1.51M	1.71%	30
2016 Q4	$24.1M	Sell	304,305 -8,350	-3%	-$607K	1.71%	28
2016 Q3	$21.9M	Sell	312,655 -76,500	-20%	-$4.24M	1.57%	27
2016 Q2	$15.1M	Sell	389,155 -15,000	-4%	-$625K	0.93%	50
2016 Q1	$16.4M	Sell	404,155 -4,760	-1%	-$302K	1%	43
2015 Q4	$36.3M	Sell	408,915 -19,380	-5%	-$1.53M	2.14%	15
2015 Q3	$31.7M	Sell	428,295 -27,630	-6%	-$2.3M	1.79%	26
2015 Q2	$36.9M	Buy	+455,925	New	+$29.7M	1.8%	22

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Ranger Investment Management's EGRX Position: Q3 2017 in Review

Ranger Investment Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2017, closing a stake of 156,717 shares — an estimated $12.4M sold.

Ranger Investment Management first reported a position in EGRX in Q2 2015 and held it in 9 quarters. The position peaked at $36.9M in Q2 2015. 169 funds tracked by Wall St. Rank hold EGRX as of Q3 2017.

Ranger Investment Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Ranger Investment Management sold 156,717 Eagle Pharmaceuticals, Inc. shares in Q3 2017, an estimated $12.4M.
Ranger Investment Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 9 quarters.
Ranger Investment Management's Eagle Pharmaceuticals, Inc. position peaked at $36.9M in Q2 2015.
169 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2017.

Based on Ranger Investment Management's 13F filing for Q3 2017, filed 14 Nov 2017.